vs

Side-by-side financial comparison of Sol-Gel Technologies Ltd. (SLGL) and Zepp Health Corp (ZEPP). Click either name above to swap in a different company.

Sol-Gel Technologies Ltd. is the larger business by last-quarter revenue ($17.3M vs $10.5M, roughly 1.7× Zepp Health Corp). Sol-Gel Technologies Ltd. runs the higher net margin — 67.3% vs -2.1%, a 69.4% gap on every dollar of revenue.

Sol-Gel Technologies Ltd. is a specialty biopharmaceutical company focused on developing and commercializing innovative dermatology treatments. Leveraging its proprietary sol-gel delivery technology, it creates topical therapies for common skin conditions including acne, rosacea and atopic dermatitis, with primary markets across North America and Europe, partnering with established healthcare firms to expand product reach.

Zepp Health Corp is a global digital health and smart wearable technology company. It develops and sells fitness trackers, smartwatches, and AI-powered health monitoring tools, serving individual consumers, sports teams, and healthcare providers across Asia, North America, and Europe, with core focus on wellness tracking and remote health management solutions.

SLGL vs ZEPP — Head-to-Head

Bigger by revenue
SLGL
SLGL
1.7× larger
SLGL
$17.3M
$10.5M
ZEPP
Higher net margin
SLGL
SLGL
69.4% more per $
SLGL
67.3%
-2.1%
ZEPP

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
SLGL
SLGL
ZEPP
ZEPP
Revenue
$17.3M
$10.5M
Net Profit
$11.6M
$-223.0K
Gross Margin
38.2%
Operating Margin
65.1%
-1.2%
Net Margin
67.3%
-2.1%
Revenue YoY
217.7%
Net Profit YoY
487.6%
EPS (diluted)
$4.17
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLGL
SLGL
ZEPP
ZEPP
Q3 25
$10.5M
Q2 25
$17.3M
$8.2M
Q1 25
$5.3M
Q3 24
$5.9M
Q2 24
$5.4M
$5.6M
Q1 24
$5.5M
Q3 23
$11.4M
Q2 23
$594.0K
$12.3M
Net Profit
SLGL
SLGL
ZEPP
ZEPP
Q3 25
$-223.0K
Q2 25
$11.6M
$-1.1M
Q1 25
$-2.7M
Q3 24
$-1.8M
Q2 24
$2.0M
$-1.5M
Q1 24
$-2.0M
Q3 23
$52.6K
Q2 23
$-6.0M
$-1.3M
Gross Margin
SLGL
SLGL
ZEPP
ZEPP
Q3 25
38.2%
Q2 25
36.2%
Q1 25
37.3%
Q3 24
40.6%
Q2 24
40.3%
Q1 24
36.8%
Q3 23
33.9%
Q2 23
22.0%
Operating Margin
SLGL
SLGL
ZEPP
ZEPP
Q3 25
-1.2%
Q2 25
65.1%
-10.3%
Q1 25
-47.7%
Q3 24
-29.5%
Q2 24
29.9%
-24.3%
Q1 24
-39.6%
Q3 23
Q2 23
-1098.8%
-11.2%
Net Margin
SLGL
SLGL
ZEPP
ZEPP
Q3 25
-2.1%
Q2 25
67.3%
-13.0%
Q1 25
-51.2%
Q3 24
-31.2%
Q2 24
36.4%
-26.7%
Q1 24
-36.8%
Q3 23
0.5%
Q2 23
-1005.1%
-10.8%
EPS (diluted)
SLGL
SLGL
ZEPP
ZEPP
Q3 25
$-0.01
Q2 25
$4.17
$-0.07
Q1 25
$-0.17
Q3 24
$-0.01
Q2 24
$0.71
$-0.01
Q1 24
$-0.01
Q3 23
Q2 23
$-0.22
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLGL
SLGL
ZEPP
ZEPP
Cash + ST InvestmentsLiquidity on hand
$24.3M
$8.7M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$31.9M
$31.2M
Total Assets
$39.3M
$80.9M
Debt / EquityLower = less leverage
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SLGL
SLGL
ZEPP
ZEPP
Q3 25
$8.7M
Q2 25
$24.3M
$7.8M
Q1 25
$10.7M
Q3 24
$16.4M
Q2 24
$26.5M
$17.0M
Q1 24
$17.9M
Q3 23
$17.9M
Q2 23
$33.5M
$19.8M
Total Debt
SLGL
SLGL
ZEPP
ZEPP
Q3 25
$9.6M
Q2 25
$9.7M
Q1 25
$9.6M
Q3 24
$5.7M
Q2 24
$7.3M
Q1 24
$11.2M
Q3 23
$16.3M
Q2 23
$16.1M
Stockholders' Equity
SLGL
SLGL
ZEPP
ZEPP
Q3 25
$31.2M
Q2 25
$31.9M
$31.1M
Q1 25
Q3 24
Q2 24
$34.9M
$44.6M
Q1 24
Q3 23
$48.0M
Q2 23
$48.3M
$47.9M
Total Assets
SLGL
SLGL
ZEPP
ZEPP
Q3 25
$80.9M
Q2 25
$39.3M
$75.8M
Q1 25
$71.6M
Q3 24
$81.3M
Q2 24
$42.0M
$79.7M
Q1 24
$80.5M
Q3 23
$91.4M
Q2 23
$55.1M
$93.8M
Debt / Equity
SLGL
SLGL
ZEPP
ZEPP
Q3 25
0.31×
Q2 25
0.31×
Q1 25
Q3 24
Q2 24
0.16×
Q1 24
Q3 23
0.34×
Q2 23
0.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons